NanoCure AI

Building intelligent platforms for biological analysis, clinical decision support, and next-generation therapeutic development.

health AIbiotechdigital healthmedtech

Visit website LinkedIn ↗

StagePre-IPO

Raised$90M

Founded2025

Employees4

LocationFrisco, TX

About

NanoCure AI is a Texas-based oncology MedTech company building cellular-intelligence systems for hematologic malignancies, blood disorders, and future extracorporeal intervention. Our platform starts with software: a hardware-agnostic Morphologic Classification System for stained blood smear images and a Flow Cytometry FCS Review workflow for .fcs files. Together, these tools generate structured per-cell outputs, reviewable overlays, candidate populations, QC context, and downloadable evidence for pathologist review. We have moved beyond lab-grown AML cell-line validation and are now testing recent de-identified primary human patient slides through Huntsman Cancer Institute, including AML and B-ALL material. Our long-term therapeutic program is a morphology-guided extracorporeal device platform that combines microscopy, AI, fluidics, embedded control, and future nanotechnology-enabled approaches to identify and process abnormal cells outside the body. NanoCure AI is building more than one product. We are building a cell-intelligence company: diagnostics first, evidence generation next, and therapeutic intervention as the long-term goal.

Product

Value proposition: Precision medicine platforms that connect biological data, clinical interpretation, and therapeutic development to enable structured, scalable, and actionable decision-making in disease analysis and treatment.
Target customers: research institutions, biotech partners, clinical researchers, healthcare organizations

Founders

Colin LeMahieu
Dmitry Schetnikovich
Patricja Pienkowski

Products

AI-guided clinical workflowstherapeutic system designinternal discovery programscomputational discovery platforms

Key features

AI-guided image-based reviewcell-level analysisstructured clinical interpretation workflowsnovel system architectures for therapeutic precisioninternal biological modeling and translational discovery

Technologies

Artificial intelligencemachine learningmedical imagingnanotechnologyadvanced opticselectromagnetic control

Partnerships

clinical research partnersstrategic and qualified clinical partners

Investors

Opulence Capital Management

News

Cheryl Danley - Head of People & Impact at NanoCure AI R&D ... · 2025-08-30T00:00:00.000Z
NeuralCure AI Launches the First Diagnostic & Digital Twin OS for Preventative Care Clinics · 2025-06-19T12:13:00.000Z
NeuralCure AI Announces Breakthrough in AI-Powered Healthcare, Completing Decades of Medical Research in Moments · 2025-02-14T13:21:00.000Z
Novartis Cyprus and Cyprus Seeds’ Teams on Strategic Exchange in Health and MedTech! - Cyprus Seeds · 2025-07-25T11:13:50.000Z
Cyprus Seeds Drives Research Commercialisation Progress with Notable Achievements — Explained (2025) · 2025-10-31T07:30:00.000Z
NeuralCure AI Launches the First Diagnostic and Digital Twin OS for Preventative Care Clinics · 2025-06-20T13:31:39.000Z

Browse similar startups

Related startups

NASSER CARDIOLOGY, P.A. — The Woodlands, TX
Oncology San Antonio Cancer Care Network — San Antonio, TX
Page Management Associates — Corpus Christi, TX
PhyTech Informatics, LLC — Dallas, TX
PIONE3R Physical Therapy & Wellness LLC — Houston, TX
Pluck Consulting Group — The Woodlands, TX
Onc.AI — San Carlos, CA
Parakeet Health — San Francisco, CA
Plexis.ai (Techstars '25) — Delaware, DE
Rovi Health (YC F25) — Philadelphia, PA
Tally — Washington, DC
Unite Genomics — San Mateo, CA

Profile updated Jul 29, 2026. Sources: nanocureaicompany.com, app.nanocureaicompany.com